# IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/il-6-receptor-inhibition-with-tocilizumab-improves-treatment-outcomes-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Paul Emery,Edward Keystone,Hans‐Peter Tony,Alain Cantagrel,Ronald van Vollenhoven,Antonio Sánchez,Emma Alecock,J. Lee,Joel M. Kremer |
| Citations | 1,117 |
| DOI | 10.1136/ard.2008.092932 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ard.bmj.com/content/annrheumdis/67/11/1516.full.pdf |
| OpenAlex ID | https://openalex.org/W2114308202 |
| PMID | 18625622 |
| Type | article |
| Year | 2008 |

## Paper authors

- [Ronald van Vollenhoven](https://scholariq.org/researchers/ronald-van-vollenhoven/)

## Paper journal

- [Annals of the Rheumatic Diseases](https://scholariq.org/journals/annals-of-the-rheumatic-diseases/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.